Cohbar

CohBar, Inc. is a clinical-stage biotechnology company focused on developing therapeutics based on mitochondrial DNA to address chronic and age-related diseases. The company operates primarily in the biotechnology and pharmaceutical markets, targeting conditions such as nonalcoholic steatohepatitis (NASH) and obesity. CohBar's business model revolves around the research, development, and commercialization of novel therapeutics. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. CohBar's flagship product, CB4211, has shown promising results in early-stage clinical trials, demonstrating significant reductions in liver damage biomarkers and glucose levels. The company serves healthcare providers, researchers, and pharmaceutical companies looking for innovative treatments for metabolic and age-related disorders.

Keywords: mitochondrial therapeutics, NASH, obesity, chronic diseases, age-related diseases, biotechnology, clinical-stage, CB4211, liver disease, metabolic disorders.